Spiral Therapeutics Raises $27M in Series B Funding

The round also saw participation from Advanced Bionics, Ferring Ventures, Uni-Bio Science Group, and other existing investors.

The company plans to use the funds to advance its pipeline programs, including SPT-2101, and expand its MICS™ platform.

At the same time as the funding, Spiral partnered with Advanced Bionics on a research and development collaboration to explore drug delivery during cochlear implant procedures, aiming to improve patient outcomes.

Spiral is developing treatments for inner ear diseases. Its main program, SPT-2101, has shown strong results in reducing vertigo in patients with Ménière’s disease, and the company is preparing for a larger clinical trial. Its MICS™ drug delivery platform also supports other programs focused on hearing loss.

Read More:Bluefish Raises $43M in Series B Funding

The inner ear is an area with few treatment advances, despite high medical need. Spiral aims to address this gap with its targeted drug delivery technology, which could expand treatment options for a range of ear related conditions.

“This funding is an important milestone for Spiral. It brings Advanced Bionics as a strategic partner, adds Gund Investment as the Series B lead, and continues the support from our existing investors,” said Hugo Peris, Founder and CEO of Spiral Therapeutics. “Inner ear diseases are now getting the attention they deserve, and Spiral is one of the few companies with a unique platform to develop a strong pipeline of treatments.”

About Spiral Therapeutics

Founded in 2016 by Hugo Peris, Spiral Therapeutics is a clinical-stage biotech company developing new treatments for inner-ear conditions, including hearing loss and balance disorders. Its MICS™ drug delivery platform is designed to deliver therapies directly and precisely to the inner ear in a minimally invasive way. The company is building a pipeline of programs to address major unmet needs in this area.

Read More:OpenGradient Raises $9.5M in Total Funding